WO2001017536A2 - Neue autovakzinen zur erzielung einer immuntoleranz - Google Patents
Neue autovakzinen zur erzielung einer immuntoleranz Download PDFInfo
- Publication number
- WO2001017536A2 WO2001017536A2 PCT/DE2000/003089 DE0003089W WO0117536A2 WO 2001017536 A2 WO2001017536 A2 WO 2001017536A2 DE 0003089 W DE0003089 W DE 0003089W WO 0117536 A2 WO0117536 A2 WO 0117536A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- new
- immune
- immune complexes
- new car
- immune tolerance
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 18
- 230000006058 immune tolerance Effects 0.000 title claims abstract description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 14
- 230000000172 allergic effect Effects 0.000 claims abstract description 3
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 239000003094 microcapsule Substances 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 230000009144 enzymatic modification Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000000470 constituent Substances 0.000 abstract 1
- 239000000306 component Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 235000003869 genetically modified organism Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
Definitions
- the invention relates to the use of immune complexes as an effective component of auto vaccines for obtaining and / or maintaining the state of immune tolerance in organisms and for the prevention and / or treatment of autoimmune diseases and diseases of an allergic basis
- Autovakzine ⁇ in the classic sense are vaccines that are made from pathogens that were isolated from the same patient in whom the vaccine is used therapeutically.
- Auto vaccines from tumor components are used to support immunotherapy for certain tumors.
- the immune system is to be activated by the administration of an auto vaccine and specifically targeted against certain pathogens or tumor cells
- Autovakzi ⁇ en in the sense of the invention are also substances that have been isolated from the organism to which they will later be used again, but not for the purpose of generating an immune response, but rather to monitor and prevent an immune response
- autoimmune diseases such as insulin-dependent diabetes (IDDM), multiple sclerosis and rheumatoid Arthritis are characterized by the destruction of the body's own parenchymatous cells by their own immune cells, ie the immune system no longer tolerates these cells
- Immune tolerance to the body's own functional and healthy cells is the basis for maintaining physical integration. Several mechanisms are responsible for their occurrence and maintenance of immune tolerance. Since 1912 it has been known that oral administration of proteins induces a state of immune tolerance for subsequent parenteral stress can
- the autoantigen ⁇ must be known and causally responsible for the maintenance of the autoimmune disease
- the Autoa ⁇ tigen must be isolated using complex methods from material of animal origin or genetically modified organisms
- the object of the invention was therefore to find substances and to package them by suitable methods in such a way that they are largely protected against the degrading action of the digestive enzymes small amounts, without genetic engineering and / or their complex cleaning, to use these substances for the prevention or therapy of autoimmune diseases.
- the invention assumes that autoimmune diseases are also characterized by the presence of circulating immune comexes and that it is possible to describe these immune complexes as effective ingredient for the production of auto vaccines to achieve immune tolerance.
- Mammals In their phylogenetic development, all mammals, including humans, have developed mechanisms which prevent the ingested foods from acting as an antigenic stimulus, so that the food supplied acts as an energy source and not as a potential antigenic burden. Mammals are immunologically tolerant of the food components that, due to their intermittent intake, maintain this tolerance for life. The same principle of regulation is addressed by the administration of the body's own substances that are recognized as foreign.
- immune complexes are obtained from the serum or plasma of patients using known methods, such as filtration, adsorption, immunoadsorption or precipitation, preferably immunoadsorption. After separating unbound immunoglobulins and other proteins, the immune complexes can be used as an effective component of a car vaccine without further processing or after cleavage into the individual components and subsequent separation and / or chemical modification.
- the immune complex components can be used in different pharmaceutical preparations, preferably in the form of capsules / microcapsules. Such preparations are suitable for restoring or maintaining the state of immune tolerance in the mammalian organism from which the immune complexes have been isolated.
- the advantage of this method is that, without knowing the cause or the cause of the disease, the autoantibodies / antikö ⁇ er are isolated from the blood or other body fluids with simple methods, which are processed into a car vaccine and placed in another body compartment, the state of immune tolerance restore.
- Known processes encapsulate immune complex components, which can be important for maintaining a necessary immune tolerance for the prevention of autoimmune diseases, in dry form or as a solution.
- the encapsulation of the autoantigens and / or autoantibodies allows the targeted application of a defined dose of the immune complex components to be applied into the small intestine, which is of crucial importance for tolerance induction.
- the car vaccines produced in this way cause a state of immune tolerance to the administered antigens by continuous absorption and thereby help to prevent the developing or already existing dysregulation of the immune reaction.
- the invention relates to the use of immune complexes (autoantigens and autoantibodies) and / or their components as an effective component of a car vaccine for regaining or maintaining the state of immune tolerance in mammalian organisms, for the prophylaxis and / or treatment of autoimmune diseases, such as e.g. Isulin-dependent diabetes (IDDM), multiple sclerosis, rheumatoid arthritis and lupus erythematosus, but also allergic reactions that are subject to a similar pathophysiological regulatory mechanism.
- IDDM Isulin-dependent diabetes
- multiple sclerosis multiple sclerosis
- rheumatoid arthritis and lupus erythematosus
- allergic reactions that are subject to a similar pathophysiological regulatory mechanism.
- the invention also relates to capsules comprising a casing material which is conventional per se, in which one or more autoantigenic substances are encapsulated, for the prophylaxis and / or treatment of autoimmune disorders, preferably IDDM, multiple sclerosis and / or rheumatoid arthritis, the antigenic substances being autoantigen and / or are autoantibodies or parts thereof and the capsules preferably have a size of 0.2 ⁇ m to 500 ⁇ m, for microcapsules preferably 0.5 ⁇ m to 20 ⁇ m.
- autoimmune disorders preferably IDDM, multiple sclerosis and / or rheumatoid arthritis
- the antigenic substances being autoantigen and / or are autoantibodies or parts thereof
- the capsules preferably have a size of 0.2 ⁇ m to 500 ⁇ m, for microcapsules preferably 0.5 ⁇ m to 20 ⁇ m.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU12675/01A AU1267501A (en) | 1999-09-07 | 2000-09-06 | Novel autogenous vaccines used to obtain an immune tolerance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19942601 | 1999-09-07 | ||
DE19942601.5 | 1999-09-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001017536A2 true WO2001017536A2 (de) | 2001-03-15 |
WO2001017536A3 WO2001017536A3 (de) | 2001-09-13 |
Family
ID=7921047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2000/003089 WO2001017536A2 (de) | 1999-09-07 | 2000-09-06 | Neue autovakzinen zur erzielung einer immuntoleranz |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU1267501A (de) |
DE (1) | DE10044129A1 (de) |
WO (1) | WO2001017536A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002522A1 (es) * | 2002-07-01 | 2004-01-08 | Suarez Mendoza Ramon | Proceso para transformar los hapigenos de un organismo causantes de enfermedades conocidas como autoinmunes en antígenos completos |
WO2005016379A1 (en) | 2003-08-15 | 2005-02-24 | The Governors Of The University Of Calgary | Compositions and methods for manipulating levels antigen-specific antibodies in a mammal |
AU2011218660B2 (en) * | 2003-08-15 | 2011-12-15 | The Governors Of The University Of Calgary | Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663049A (en) * | 1984-07-05 | 1987-05-05 | University Of Utah | Process for therapeutic dissociation of immune complexes and removal of antigens |
WO1991009619A1 (en) * | 1990-01-03 | 1991-07-11 | International Institute Of Cellular And Molecular Pathology | Pharmaceutical compositions containing antigen-antibody complexes and uses therefor |
US5783193A (en) * | 1991-06-21 | 1998-07-21 | The University Of Cincinnati | Oral administration of therapeutic proteins for treatment of autoimmune disease, transplant rejection and infectious disease |
DE19714913A1 (de) * | 1995-10-05 | 1998-10-08 | Privates Inst Bioserv Gmbh | Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren zu deren Herstellung |
-
2000
- 2000-09-06 DE DE10044129A patent/DE10044129A1/de not_active Withdrawn
- 2000-09-06 AU AU12675/01A patent/AU1267501A/en not_active Abandoned
- 2000-09-06 WO PCT/DE2000/003089 patent/WO2001017536A2/de active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663049A (en) * | 1984-07-05 | 1987-05-05 | University Of Utah | Process for therapeutic dissociation of immune complexes and removal of antigens |
WO1991009619A1 (en) * | 1990-01-03 | 1991-07-11 | International Institute Of Cellular And Molecular Pathology | Pharmaceutical compositions containing antigen-antibody complexes and uses therefor |
US5783193A (en) * | 1991-06-21 | 1998-07-21 | The University Of Cincinnati | Oral administration of therapeutic proteins for treatment of autoimmune disease, transplant rejection and infectious disease |
DE19714913A1 (de) * | 1995-10-05 | 1998-10-08 | Privates Inst Bioserv Gmbh | Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren zu deren Herstellung |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002522A1 (es) * | 2002-07-01 | 2004-01-08 | Suarez Mendoza Ramon | Proceso para transformar los hapigenos de un organismo causantes de enfermedades conocidas como autoinmunes en antígenos completos |
WO2005016379A1 (en) | 2003-08-15 | 2005-02-24 | The Governors Of The University Of Calgary | Compositions and methods for manipulating levels antigen-specific antibodies in a mammal |
EP1653999A1 (de) * | 2003-08-15 | 2006-05-10 | The Governors of the university of Calgary | Zusammensetzungen und verfahren zur manipulation der spiegel antigenspezifischer antikörper in einem säuger |
EP1653999A4 (de) * | 2003-08-15 | 2007-10-03 | Univ Alberta | Zusammensetzungen und verfahren zur manipulation der spiegel antigenspezifischer antikörper in einem säuger |
AU2011218660B2 (en) * | 2003-08-15 | 2011-12-15 | The Governors Of The University Of Calgary | Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal |
Also Published As
Publication number | Publication date |
---|---|
DE10044129A1 (de) | 2001-05-17 |
AU1267501A (en) | 2001-04-10 |
WO2001017536A3 (de) | 2001-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69722217T2 (de) | Verewndung von hyperimmunisierte milch und/oder ei zur behandlung von magen-darm verletzungen | |
DE69831971T2 (de) | Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer | |
DE69332518T2 (de) | Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung | |
DE69133516T2 (de) | Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen | |
DE3854741T3 (de) | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen. | |
DE69409962T2 (de) | Immuntoleranzinduzierendes agens | |
DE3689717T2 (de) | Einen spezifischen Antikörper enthaltender Stoff aus Eiern, Verfahren zu dessen Herstellung und seine Anwendung. | |
CH644521A5 (de) | Therapeutisches immunosuppressives mittel und verfahren zu dessen herstellung. | |
DE3504221A1 (de) | Verfahren zur passiven immunisierung von saeugern unter verwendung von antikoerpern von gefluegel und/oder boviden und antikoerpergemische | |
DE3444765A1 (de) | Immunmodulierendes arzneimittel | |
DE69816796T2 (de) | Pharmazeutische oder nahrungsmittelzusammensetzung für die behandlung von pathologien die assoziiert sind mit einem transplantatabstoss, einer allergischen oder autoimmunreaktion | |
DE69830900T2 (de) | Immunologische toleranz-induzierende zusammensetzungen enthaltend antigen und mucosabindungskomponente | |
DE69432930T2 (de) | Immunmodulierende zusammensetzungen aus galle | |
WO2004004750A2 (de) | Verwendung von inhibitoren der alanyl-aminopeptidasen und diese umfassende pharmazeutischen zubereitungen | |
DE69007799T2 (de) | Pharmazeutische antigen-antikörper-komplexe enthaltende zusammensetzungen und deren anwendungen. | |
DE69813070T2 (de) | Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex | |
WO2001017536A2 (de) | Neue autovakzinen zur erzielung einer immuntoleranz | |
EP0756605A1 (de) | Peptide als therapeutikum für autoimmunerkrankungen | |
DE69527640T2 (de) | Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten | |
US5863561A (en) | Immune suppressive product | |
AU648800B2 (en) | Immune suppressive product | |
WO2012136522A1 (de) | Antikörperprodukt, umfassend n spezifische antikörper | |
JPH06510752A (ja) | アレルギー治療のためのp物質の使用方法 | |
WO2011150235A1 (en) | Methods and reagents for treating autoimmune disorders and/or graft rejection | |
DE3827490C2 (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |